Radiation-induced tumors and secondary malignancies following radiotherapy

Jelena Dedović Stojaković; Luka Jovanović; Predrag Filipović; Tamara Marinković; Mladen Marinković; Vukač Vujanac; Vesna Plešinac Karapandžić

doi:10.2298/VSP201210017D

Jelena Dedović Stojaković Institute for Oncology and Radiology of Serbia, Department of Radiation Oncology, Belgrade, Serbia
Luka Jovanović Institute for Oncology and Radiology of Serbia, Department of Radiation Oncology, Belgrade, Serbia
Predrag Filipović Institute for Oncology and Radiology of Serbia, Department of Radiation Oncology, Belgrade, Serbia
Tamara Marinković Institute for Oncology and Radiology of Serbia, Department of Radiation Oncology, Belgrade, Serbia
Mladen Marinković Institute for Oncology and Radiology of Serbia, Department of Radiation Oncology, Belgrade, Serbia
Vukač Vujanac Institute for Oncology and Radiology of Serbia, Department of Radiation Oncology, Belgrade, Serbia
Vesna Plešinac Karapandžić Institute for Oncology and Radiology of Serbia, Department of Radiation Oncology, Belgrade, Serbia

DOI: https://doi.org/10.2298/VSP201210017D

Keywords: genetics, neoplasms metastasis, neoplasms, radiation-induced, radiotherapy, risk assessment, survival

References

Lievens Y, Borras JM, Grau C. Provision and use of radiothera-py in Europe. Mol Oncol 2020l; 14(7): 1461‒9.

Dracham CB, Shankar A, Madan R. Radiation-induced second-ary malignancies: a review article. Radiat Oncol J 2018; 36(2): 85‒94.

Cahan WG, Woodard HQ, Higinbotham NL, Stewart FW, Coley BL. Sarcoma arising in irradiated bone: report of eleven cases. 1948. Cancer 1998; 82(1): 8‒34.

Singh GK, Yadav V, Singh P, Bhowmik KT. Radiation-Induced Malignancies Making Radiotherapy a "Two-Edged Sword": A Review of Literature. World J Oncol 2017; 8(1): 1‒6.

Zheng X, Li X, Wang M, Shen J, Sisti G, He Z, et al. Multidis-ciplinary Oncology Research Collaborative Group (MORCG). Second primary malignancies among cancer patients. Ann Transl Med 2020; 8(10): 638.

Zwicker F, Kirchner C, Huber PE, Debus J, Zwicker H, Klepper R. Breast cancer occurrence after low dose radiotherapy of non-malignant disorders of the shoulder. Sci Rep 2019; 9(1): 5301.

Meadows A, Friedman D, Neglia J, Mertens A, Sarah S. Donaldson S, et al. Second Neoplasms in Survivors of Childhood Cancer: Findings from the Childhood Cancer Survivor Study Cohort. J Clin Oncol 2009; 27(14): 2356–62.

Zakaria D, Shaw A, Xie L. Risk of a second cancer in Canadi-ans diagnosed with a first cancer in childhood or adolescence. EClinicalMedicine 2019; 16: 107–20.

Kumar S. Second malignant neoplasms following radiotherapy. Int J Environ Res Public Health 2012; 9(12): 4744‒59.

Armstrong GT, Sklar CA, Hudson MM, Robison LL. Long-term health status among survivors of childhood cancer: does sex matter? J Clin Oncol 2007; 25(28): 4477‒89.

Cooke R, Jones ME, Cunningham D, Falk SJ, Gilson D, Hancock BW, et al. Breast cancer risk following Hodgkin lymphoma ra-diotherapy in relation to menstrual and reproductive factors. Br J Cancer 2013; 108(11): 2399‒406.

Schneider U, Sumila M, Robotka J. Site-specific dose-response relationships for cancer induction from the combined Japanese A-bomb and Hodgkin cohorts for doses relevant to radiother-apy. Theor Biol Med Model 2011; 8: 27.

Teepen JC, van Leeuwen FE, Tissing WJ, van Dulmen-den Broeder E, van den Heuvel-Eibrink MM, van der Pal HJ, et al. Long-Term Risk of Subsequent Malignant Neoplasms After Treatment of Childhood Cancer in the DCOG LATER Study Cohort: Role of Chemotherapy. J Clin Oncol 2017; 35(20): 2288‒98.

Bassal M, Mertens AC, Taylor L, Neglia JP, Greffe BS, Hammond S, et al. Risk of selected subsequent carcinomas in survivors of childhood cancer: a report from the Childhood Cancer Survi-vor Study. J Clin Oncol 2006; 24(3): 476‒83.

Fung C, Fossa SD, Milano MT, Oldenburg J, Travis LB. Solid tumors after chemotherapy or surgery for testicular nonsemi-noma: a population-based study. J Clin Oncol 2013; 31(30): 3807‒14.

Tiruneh T, Enawgaw B, Shiferaw E. Genetic Pathway in the Pathogenesis of Therapy-Related Myeloid Neoplasms: A Lit-erature Review. Oncol Ther 2020; 8(1): 45‒57.

Brenner DJ, Doll R, Goodhead DT, Hall EJ, Land CE, Little JB, et al. Cancer risks attributable to low doses of ionizing radia-tion: assessing what we really know. Proc Natl Acad Sci U S A 2003; 100(24): 13761‒6.

Salminen SH, Sampo MM, Böhling TO, Tuomikoski L, Tarkkanen M, Blomqvist CP. Radiation-associated sarcoma after breast cancer in a nationwide population: Increasing risk of angiosar-coma. Cancer Med 2018; 7(9): 4825‒35.

Cohen-Hallaleh RB, Smith HG, Smith RC, Stamp GF, Al-Muderis O, Thway K, et al. Radiation induced angiosarcoma of the breast: outcomes from a retrospective case series. Clin Sar-coma Res 2017; 7: 15.

Grantzau T, Overgaard J. Risk of second non-breast cancer after radiotherapy for breast cancer: a systematic review and meta-analysis of 762,468 patients. Radiother Oncol 2015; 114(1): 56‒65.

Berrington de Gonzalez A, Curtis RE, Gilbert E, Berg CD, Smith SA, Stovall M, et al. Second solid cancers after radiotherapy for breast cancer in SEER cancer registries. Br J Cancer 2010; 102(1): 220‒6.

Mladenovic J, Susnjar S, Tanic M, Jankovic R, Karadzic K, Gavrilo-vic D, et al. Tumor response and patient outcome after pre-operative radiotherapy in locally advanced non-inflammatory breast cancer patients. J BUON 2017; 22(2): 325‒33.

Fontenot JD, Lee AK, Newhauser WD. Risk of secondary malig-nant neoplasms from proton therapy and intensity-modulated X-ray therapy for early-stage prostate cancer. Int J Radiat On-col Biol Phys 2009; 74(2): 616–22.

Brenner DJ, Curtis RE, Hall EJ, Ron E. Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer 2000; 88(2): 398‒406.

Chaturvedi AK, Engels EA, Gilbert ES, Chen BE, Storm H, Lynch CF, et al. Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk. J Natl Cancer Inst 2007; 99(21): 1634‒43.

Rodriguez AM, Kuo YF, Goodwin JS. Risk of colorectal cancer among long-term cervical cancer survivors. Med Oncol 2014; 31(5): 943.

Creutzberg CL, Nout RA, Lybeert ML, Wárlám-Rodenhuis CC, Jobsen JJ, Mens JW, et al. Fifteen-year radiotherapy outcomes of the randomized PORTEC-1 trial for endometrial carcino-ma. Int J Radiat Oncol Biol Phys 2011; 81(4): e631‒8.

Hodgson DC, Gilbert ES, Dores GM, Schonfeld SJ, Lynch CF, Storm H, et al. Long-Term Solid Cancer Risk Among 5-Year Survivors of Hodgkin’s Lymphoma. J Clin Oncol 2007; 25(12): 1489‒97.

Tward JD, Wendland MM, Shrieve DC, Szabo A, Gaffney DK. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma. Cancer 2006; 107(1): 108‒15.

Friedman DL, Whitton J, Leisenring W, Mertens AC, Hammond S, Stovall M, et al. Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst 2010; 102(14): 1083‒95.

Robison LL, Hudson MM. Survivors of childhood and adoles-cent cancer: life-long risks and responsibilities. Nat Rev Can-cer 2014; 14(1): 61‒70.

Bergom C, West CM, Higginson DS, Abazeed ME, Arun B, Bentzen SM, et al. The Implications of Genetic Testing on Ra-diation Therapy Decisions: A Guide for Radiation Oncolo-gists. Int J Radiat Oncol Biol Phys 2019; 105(4): 698‒712.

Burt LM, Ying J, Poppe MM, Suneja G, Gaffney DK. Risk of sec-ondary malignancies after radiation therapy for breast cancer: Comprehensive results. Breast 2017; 35: 122‒9.

Kleinerman RA. Radiation-sensitive genetically susceptible pe-diatric sub-populations. Pediatr Radiol 2009; 39(Suppl 1): S27‒31.

Dong L, Cui J, Tang F, Cong X, Han F. Ataxia telangiectasia-mutated gene polymorphisms and acute normal tissue injuries in cancer patients after radiation therapy: a systematic review and meta-analysis. Int J Radiat Oncol Biol Phys 2015; 91(5): 1090‒8.

Huszno J, Budryk M, Kołosza Z, Nowara E. The influence of BRCA1/BRCA2 mutations on toxicity related to chemother-apy and radiotherapy in early breast cancer patients. Oncology 2013; 85(5): 278‒82.

Berrington de Gonzalez A, Curtis RE, Kry SF, Gilbert E, Lamart S, Berg CD, et al. Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. Lancet Oncol 2011; 12(4): 353‒60.

Tanić M, Krivokuća A, Čavić M, Mladenović J, Plesinac Karapandžić V, Beck S, et al. Molecular signature of response to preopera-tive radiotherapy in locally advanced breast cancer. Radiat Oncol 2018; 13(1): 193.

Best T, Li D, Skol AD, Kirchhoff T, Jackson SA, Yasui Y, et al. Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma. Nat Med 2011; 17(8): 941‒3.

Huang SC, Zhang L, Sung YS, Chen CL, Kao YC, Agaram NP, et al. Recurrent CIC Gene Abnormalities in Angiosarcomas: A Molecular Study of 120 Cases with Concurrent Investigation of PLCG1, KDR, MYC, and FLT4 Gene Alterations. Am J Surg Pathol 2016; 40(5): 645‒55.

Ginter PS, Mosquera JM, MacDonald TY, D'Alfonso TM, Rubin MA, Shin SJ. Diagnostic utility of MYC amplification and an-ti-MYC immunohistochemistry in atypical vascular lesions, primary or radiation-induced mammary angiosarcomas, and primary angiosarcomas of other sites. Hum Pathol 2014; 45(4): 709‒16.

Knopf A, Lempart J, Bas M, Slotta-Huspenina J, Mansour N, Fritsche MK. Oncogenes and tumor suppressor genes in squa-mous cell carcinoma of the tongue in young patients. Onco-target 2015; 6(5): 3443‒51.

Mak RH, Hermann G, Lewis JH, Aerts HJWL, Baldini EH, Chen AB, et al. Outcomes by tumor histology and KRAS mu-tation status after lung stereotactic body radiation therapy for early-stage non-small-cell lung cancer. Clin Lung Cancer 2015; 16(1): 24‒32.

Jackson SP, Bartek J. The DNA-damage response in human biol-ogy and disease. Nature 2009; 461(7267): 1071‒8.

Hall EJ. Cancer caused by x-rays--a random event? Lancet Oncol 2007; 8(5): 369‒70.

Laramore GE. Role of particle radiotherapy in the manage-ment of head and neck cancer. Curr Opin Oncol 2009; 21(3): 224‒31.

Suzuki M, Watanabe M, Suzuki K, Nakano K, Kaneko I. Neo-plastic cell heavy ions. Radiat Res 1989; 120(3): 468‒76.

Brenner DJ, Hall EJ. Secondary neutrons in clinical proton ra-diotherapy: a charged issue. Radiother Oncol 2008; 86(2): 165‒70.

Eaton BR, MacDonald SM, Yock TI, Tarbell NJ. Secondary Ma-lignancy Risk Following Proton Radiation Therapy. Front Oncol 2015; 5: 261.

Chung CS, Yock TI, Nelson K, Xu Y, Keating NL, Tarbell NJ. In-cidence of second malignancies among patients treated with proton versus photon radiation. Int J Radiat Oncol Biol Phys 2013; 87(1): 46‒52.

Marjanovic D, Plesinac Karapandzic V, Stojanovic Rundic S, To-masevic A, Saric M, Miskovic I, et al. Implementation of intensi-ty-modulated radiotherapy and comparison with three-dimensional conformal radiotherapy in the postoperative treatment of cervical cancer. J BUON 2019; 24(5): 2028‒34.

Marjanovic D, Plesinac Karapandzic V, Stojanovic Rundic S, To-masevic A, Saric M, Miskovic I, et al. Acute toxicity of postop-erative intensity-modulated radiotherapy and three-dimensional conformal radiotherapy for cervical cancer: The role of concomitant chemotherapy. J BUON 2019; 24(6): 2347‒54.

Hall EJ, Wuu CS. Radiation-induced second cancers: the im-pact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys 2003; 56(1): 83‒8.

Zwahlen DR, Ruben JD, Jones P, Gagliardi F, Millar JL, Schneider U. Effect of intensity-modulated pelvic radiotherapy on sec-ond cancer risk in the postoperative treatment of endometrial and cervical cancer. Int J Radiat Oncol Biol Phys 2009; 74(2): 539‒45.

Tomasevic A, Plesinac Karapandzic V, Stojanovic Rundic S, Vuckovic S, Milinkovic P, Gavrilovic D, et al. 3D MRI-based evaluation of the 2D brachytherapy planning in patients with advanced cer-vical cancer: An analysis of the delivered dose. J BUON 2020; 25(1): 108‒15.